Abstract:Synthetic lethal (SL) interactions occur when alterations in two genes lead to cell death but alteration in only one of them is not lethal. SL interactions provide a new strategy for molecular-targeted cancer therapy. Currently, there are few drugs targeting SL interactions that entered into clinical trials. Therefore, it is necessary to investigate the link between SL interactions and drug sensitivity of cancer cells systematically for drug development purpose. We identified SL interactions by integrating the high-throughput data from The Cancer Genome Atlas, small hairpin RNA data and genetic interactions of yeast. By integrating SL interactions from other studies, we tested whether the SL pairs that consist of drug target genes and the genes with genomic alterations are related with drug sensitivity of cancer cells. We found that only 6.26%∼34.61% of SL interactions showed the expected significant drug sensitivity using the pooled cancer cell line data from different tissues, but the proportion increased significantly to approximately 90% using the cancer cell line data for each specific tissue. From an independent pharmacogenomics data of 41 breast cancer cell lines, we found three SL interactions (ABL1-IFI16, ABL1-SLC50A1 and ABL1-SYT11) showed significantly better prognosis for the patients with both genes being altered than the patients with only one gene being altered, which partially supports the SL effect between the gene pairs. Our study not only provides a new way for unraveling the complex mechanisms of drug sensitivity but also suggests numerous potentially important drug targets for cancer therapy.

The Role of Drug-Metabolizing Enzymes in Synthetic Lethality of Cancer.

Synthetic Lethality: a Promising Therapeutic Strategy for Hepatocellular Carcinoma.

Synthetic Lethality in Drug Development: the Dawn is Coming

Synthetic lethal strategies for the development of cancer therapeutics

Synthetic Lethal Interactions in Cancer Therapy

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy Through Synergistic Integration with Chemotherapy Drugs

Synthetic lethality as an engine for cancer drug target discovery

Research Progress for the Development of Anti-Tumor Drugs Based on Synthetic Lethality

The power and the promise of synthetic lethality for clinical application in cancer treatment

Synthetic Lethality in Personalized Cancer Therapy

Systematic Analysis of Cancer-Specific Synthetic Lethal Interactions Provides Insight into Personalized Anticancer Therapy.

Epigenetic Based Synthetic Lethal Strategies in Human Cancers

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

Complex synthetic lethality in cancer

Synthetic lethal screen and its use in cancer related research

Exploiting synthetic lethal vulnerabilities for cancer therapy

Link Synthetic Lethality to Drug Sensitivity of Cancer Cells.

SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment

Collateral Lethality: A Unique Type of Synthetic Lethality in Cancers